면역치료 관련 연구

항암 면역세포 치료제

삼중음성 유방암에 대한 CIK(싸이토카인 유도 살해세포) 치료 효과adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6713632/

** 2009년 1월부터 2015년 1월까지 총 294명의 삼중음성 유방암 환자가 수술 후 연구에 참여함.
생존 분석 결과 화학항암제와 CIK세포를 병용 투여한 결과 특히 6회 이상 CIK를 투여받은 환자들에게서 무질병성 생존률과 전반적인 생존률의 차이가 더 커 매우 우수한 임상적 효과를 보였다.
A total of 294 post-surgery TNBC patients participated in the research from January 1, 2009 to January 1, 2015. After adjuvant chemotherapy, autologous CIK cells were introduced in 147 cases (CIK group), while adjuvant chemotherapy alone was used to treat the remaining 147 cases (control group). The major endpoints of the investigation were the disease-free survival (DFS) and overall survival (OS).

Survival analysis showed that the patients treated for more than 6 cycles with CIK cells had greater DFS and OS intervals than those treated with less than 6 cycles.

* CIK Cell = 항암면역세포 치료제 주성분